HYDROCHLOROTHIAZIDE (HCTZ) USE IS ASSOCIATED WITH INCREASED RISK OF BASAL CELL AND SQUAMOUS CELL CARCINOMA

A recent study published in the Journal of the American Academy of Dermatology has shown that taking hydrochlorothiazide (HCTZ) is associated with an increased risk of basal cell carcinoma and an even higher risk of squamous cell carcinoma. The risk was dose dependent (the higher the cumulative dose, the higher the risk).

An increased risk was not seen with other anti-hypertensive agents or diuretics.

Robert S. Bader, M.D., Dermatologist

Categories

Subscribe!